MYLK2 Antibody - #DF9023

(1)   (4)  
Product: MYLK2 Antibody
Catalog: DF9023
Description: Rabbit polyclonal antibody to MYLK2
Application: WB IF/ICC
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 65 kDa; 65kD(Calculated).
Uniprot: Q9H1R3
RRID: AB_2842219

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
IF/ICC 1:100-1:500, WB 1:1000-3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(100%), Zebrafish(86%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
MYLK2 Antibody detects endogenous levels of total MYLK2.
RRID:
AB_2842219
Cite Format: Affinity Biosciences Cat# DF9023, RRID:AB_2842219.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

KMLC; MLCK; MLCK, skeletal/cardiac; MLCK2; MYLK 2; MYLK2; MYLK2_HUMAN; Myosin light chain kinase 2; Myosin light chain kinase 2 skeletal muscle; Myosin light chain kinase 2 skeletal/cardiac muscle; MYOSIN LIGHT POLYPEPTIDE KINASE; Myosin light polypeptide kinase, skeletal/cardiac; Skeletal muscle myosin light chain kinase; Skeletal myosin light chain kinase; skeletal/cardiac muscle; skMLCK;

Immunogens

Immunogen:
Uniprot:

Q9H1R3(MYLK2_HUMAN) >>Visit HPA database.

Gene(ID):
MYLK2(85366)
Expression:
Q9H1R3 MYLK2_HUMAN:

Heart and skeletal muscles. Increased expression in the apical tissue compared to the interventricular septal tissue.

Sequence:
MATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGV

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
100
Zebrafish
86
Xenopus
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9H1R3 As Substrate

Site PTM Type Enzyme
S143 Phosphorylation
S151 Phosphorylation P49137 (MAPKAPK2)
K561 Ubiquitination
Y563 Phosphorylation
K584 Ubiquitination
S586 Phosphorylation
S587 Phosphorylation
S588 Phosphorylation

PTMs - Q9H1R3 As Enzyme

Substrate Site Source
Q06413 (MEF2C) T80 Uniprot

Research Backgrounds

Function:

Implicated in the level of global muscle contraction and cardiac function. Phosphorylates a specific serine in the N-terminus of a myosin light chain.

Subcellular Location:

Cytoplasm.
Note: Colocalizes with phosphorylated myosin light chain (RLCP) at filaments of the myofibrils.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Heart and skeletal muscles. Increased expression in the apical tissue compared to the interventricular septal tissue.

Subunit Structure:

May interact with centrin.

Family&Domains:

Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > Calcium signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway.   (View pathway)

· Organismal Systems > Circulatory system > Vascular smooth muscle contraction.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Digestive system > Gastric acid secretion.

References

1). Inhibition of Peripheral ERK Signaling Ameliorates Persistent Muscle Pain Around Trigger Points in Rats. Cell Transplantation (PubMed: 33081508) [IF=3.3]

Application: WB    Species: rat    Sample: muscle

Figure 6. |MLCK might be the target of the ERK inhibitor involved in ameliorating muscular mechanical hyperalgesia. (B) The expression of MLCK protein. MLCK expression was increased in the MPS group compared with that in the control group. MLCK expression was decreased in the ERK inhibitor group compared with that in the MPS group.

Application: WB    Species: Rat    Sample: muscle tissue

Figure 6. MLCK might be the target of the ERK inhibitor involved in ameliorating muscular mechanical hyperalgesia. (A) The relationship between ERK and MLCK was shown by bioinformatics prediction with the STRING database. (B) The expression of MLCK protein. MLCK expression was increased in the MPS group compared with that in the control group. MLCK expression was decreased in the ERK inhibitor group compared with that in the MPS group. Data are presented as the mean ± SEM (n = 6). The data were analyzed using one-way ANOVA. **P < 0.01. (C) The expression of p-MLC protein. p-MLC expression was increased in the MPS group compared with that in the control group. p-MLC expression was decreased in the ERK inhibitor group compared with that in the MPS group. Data are presented as the mean ± SEM (n = 6). The data were analyzed using one-way ANOVA. **P < 0.01. ANOVA: analysis of variance; MLCK: myosin light chain kinase; MPS: myofascial pain syndrome; SEM: standard error of the mean.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.